CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced it will host a virtual KOL Event on December 4, 2023 at 12:00 PM ET to discuss the positive topline results recently announced from Part 2 of Phase 1b/2a trial of BX004 in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) infections. To register for the event, please click here.
The event will feature Dr. Eitan Kerem, M.D. (Hadassah University Medical Center) and Dr. Robert T. "Chip" Schooley, M.D. (University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.
Jonathan Solomon, Chief Executive Officer of BiomX, will review topline results from Part 2 of the Phase 1b/2a trial evaluating the Company's novel phage cocktail, BX004, as a potential treatment for chronic pulmonary infections caused by P. aeruginosa in CF patients.
BiomX is developing BX004, utilizing its proprietary BOLT platform, to address a significant unmet need facing thousands of CF patients who require new treatments to combat persistent and deadly lung infections. P. aeruginosa is a main contributor to morbidity and mortality in patients with CF.
A live question and answer session will follow the formal presentations.
About Dr. Eitan Kerem, M.D.
Dr. Eitan Kerem, M.D., Professor of Pediatrics, is the former Chairman of the Department of Pediatrics at the Pediatric Pulmonology Unit of the Hadassah University Medical Center in Jerusalem and former board member of the European Cystic Fibrosis Society. Professor Kerem built the Pulmonary and Cystic Fibrosis Clinic of the Shaare Zedek Medical Center in Jerusalem, and subsequently he was elected Head of the Department of Pediatrics at the Hadassah Medical Center, and Professor in Pediatrics at the Hebrew University–Hadassah Medical School in 2002. In 2011, he was appointed as Chairman of Pediatrics at the Hadassah University Medical Center.
Professor Kerem's interest in cystic fibrosis (CF) spans all aspects of the condition. He was involved in formulating the guidelines that paved the road to the standardization of CF care in Europe and other parts of the world. He has been a principal investigator in many national and international multicenter clinical trials in CF and is an author of key publications in this field.
Professor Kerem was Chairman of the Medical Advisory Board for the Israeli CF Foundation and served as a board member of the European Cystic Fibrosis ...